Nordicus Partners Corporation (NORD)
NASDAQ: NORD · Real-Time Price · USD
2.800
-0.130 (-4.44%)
At close: Nov 20, 2026, 4:00 PM EST
2.340
-0.460 (-16.43%)
After-hours: Nov 20, 2026, 4:29 PM EST
Nordicus Partners Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
54.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | - | - | - |
| Mar 31, 2025 | 5.00K | 2.50K | 100.00% |
| Mar 31, 2024 | 2.50K | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 148.22M |
| Tonix Pharmaceuticals Holding | 43.05M |
| Spero Therapeutics | 41.56M |
| Verrica Pharmaceuticals | 22.89M |
| Werewolf Therapeutics | 21.00M |
| RenovoRx | 2.78M |
| Impact BioMedical | 38.00K |
NORD News
- 22 days ago - Nordicus Partners Corporation Announces Uplisting to The Nasdaq Capital Market - GlobeNewsWire
- 2 months ago - Nordicus Partners Corporation Appoints Elizabeth Addonizio to Its Board of Directors - GlobeNewsWire
- 5 months ago - Nordicus Partners Corporation Corporate Update - GlobeNewsWire
- 1 year ago - NoviThera has initiated the first efficacy animal studies - GlobeNewsWire
- 1 year ago - Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats. - GlobeNewsWire
- 1 year ago - Orocidin develops novel cGMP manufacturing process in collaboration with Syngene - GlobeNewsWire
- 1 year ago - Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApS - GlobeNewsWire
- 1 year ago - Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital Market - GlobeNewsWire